Jan Vermorken

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Wouters An; Pauwels Bea; Lambrechts Hilde A J; Pattyn Greet G O; Ides Johan; Baay Marc; Meijnders Paul; Dewilde Sylvia; Vermorken Jan B; Lardon Filip
Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model.
Pauwels B; Vermorken J B; Wouters A; Ides J; Van Laere S; Lambrechts H A J; Pattyn G G O; Vermeulen K; Meijnders P; Lardon F
The role of apoptotic cell death in the radiosensitising effect of gemcitabine.
Vermorken Jan B
Annals of oncology: some modest proposals but some great aims.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jan Vermorken (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Wouters An; Pauwels Bea; Lambrechts Hilde A J; Pattyn Greet G O; Ides Johan; Baay Marc; Meijnders Paul; Dewilde Sylvia; Vermorken Jan B; Lardon Filip
Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model.
Cancer letters 2009;286(2):180-8.
2009: Pauwels B; Vermorken J B; Wouters A; Ides J; Van Laere S; Lambrechts H A J; Pattyn G G O; Vermeulen K; Meijnders P; Lardon F
The role of apoptotic cell death in the radiosensitising effect of gemcitabine.
British journal of cancer 2009;101(4):628-36.
2009: Vermorken Jan B
Annals of oncology: some modest proposals but some great aims.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1289-90.
2009: Specenier Pol M; Ciuleanu Tudor; Latz Jane E; Musib Luna C; Darstein Christelle L S; Vermorken Jan B
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Cancer chemotherapy and pharmacology 2009;64(2):233-41.
2009: Bernier Jacques; Bentzen Søren M; Vermorken Jan B
Molecular therapy in head and neck oncology.
Nature reviews. Clinical oncology 2009;6(5):266-77.
2009: Michiels Stefan; Le Maître Aurélie; Buyse Marc; Burzykowski Tomasz; Maillard Emilie; Bogaerts Jan; Vermorken Jan B; Budach Wilfried; Pajak Thomas F; Ang Kian K; Bourhis Jean; Pignon Jean-Pierre;
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
The lancet oncology 2009;10(4):341-50.
2009: Specenier Pol M; Vermorken Jan B
Current concepts for the management of head and neck cancer: chemotherapy.
Oral oncology 2009;45(4-5):409-15.
2009: Altintas Sevilay; Lambein Kathleen; Huizing Manon T; Braems Geert; Asjoe Fernando Tjin; Hellemans Hilde; Van Marck Eric; Weyler Joost; Praet Marleen; Van den Broecke Rudy; Vermorken Jan B; Tjalma Wiebren A
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
The breast journal 2009;15(2):120-32.
2009: Van den Wyngaert Tim; Huizing Manon T; Fossion Eric; Vermorken Jan B
Bisphosphonates in oncology: rising stars or fallen heroes.
The oncologist 2009;14(2):181-91.
2009: Van den Wyngaert T; Claeys T; Huizing M T; Vermorken J B; Fossion E
Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(2):331-6.
2009: Specenier Pol M; Weyler Joost; Van Laer Carl; Van den Weyngaert Danielle; Van den Brande Jan; Huizing Manon T; Altintas Sevilay; Vermorken Jan B
A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
BMC cancer 2009;9():273.
2009: Baay M F D; Nakonieczny M; Wozniak I; Deschoolmeester V; Liss J; Lukaszuk K; Sotlar K; Emerich J; Vermorken J B
Microsatellite instability and HPV genotype in Polish women with cervical cancer.
European journal of gynaecological oncology 2009;30(2):162-6.
2008: Deschoolmeester Vanessa; Van Damme Nancy; Baay Marc; Claes Kathleen; Van Marck Eric; Baert Filip J; Wuyts Wim; Cabooter Marc; Weyler Joost; Vermeulen Peter; Lardon Filip; Vermorken Jan B; Peeters Marc
Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population.
European journal of cancer (Oxford, England : 1990) 2008;44(15):2288-95.
2008: Vermorken Jan B; Mesia Ricard; Rivera Fernando; Remenar Eva; Kawecki Andrzej; Rottey Sylvie; Erfan Jozsef; Zabolotnyy Dmytro; Kienzer Heinz-Roland; Cupissol Didier; Peyrade Frederic; Benasso Marco; Vynnychenko Ihor; De Raucourt Dominique; Bokemeyer Carsten; Schueler Armin; Amellal Nadia; Hitt Ricardo
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
The New England journal of medicine 2008;359(11):1116-27.
2008: Rapidis Alexander D; Vermorken Jan B; Bourhis Jean
Targeted therapies in head and neck cancer: past, present and future.
Reviews on recent clinical trials 2008;3(3):156-66.
2008: Simoens Cindy; Pauwels Bea; Vermorken Jan B; Pattyn Greet G O; Lambrechts Hilde A J; Breillout Fabienne; Lardon Filip
Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro.
Cancer chemotherapy and pharmacology 2008;62(2):183-93.
2008: Posner Marshall; Vermorken Jan B
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Seminars in oncology 2008;35(3):221-8.
2008: Vermorken Jan B; Herbst Roy S; Leon Xavier; Amellal Nadia; Baselga Jose
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Cancer 2008;112(12):2710-9.
2008: Baak J P A; van Diest P J; Janssen E A M; Gudlaugsson E; Voorhorst F J; van der Wall E; Vermorken J B;
Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(4):649-54.
2008: Specenier Pol M; Vermorken Jan B
Recurrent head and neck cancer: current treatment and future prospects.
Expert review of anticancer therapy 2008;8(3):375-91.
2008: Vermorken J B
Second-line randomized trials in epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():59-66.
2008: Deschoolmeester Vanessa; Baay Marc; Wuyts Wim; Van Marck Eric; Van Damme Nancy; Vermeulen Peter; Lukaszuk Krzysztof; Lardon Filip; Vermorken Jan B
Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers.
The Journal of molecular diagnostics : JMD 2008;10(2):154-9.
2008: Simoens Cindy; Lardon Filip; Pauwels Bea; De Pooter Christel M J; Lambrechts Hilde A J; Pattyn Greet G O; Breillout Fabienne; Vermorken Jan B
Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.
BMC cancer 2008;8():65.
2007: Grootenboers Marco Jj H; Hendriks Jeroen M H; van Boven Wim J; Knibbe Catherijne A J; van Putte Bart; Stockman Bernard; De Bruijn Ernst; Vermorken Jan B; Van Schil Paul E Y; Schramel Franz Mnh
Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Journal of surgical oncology 2007;96(7):583-9.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Calvert Hilary; Boddy Alan V; Hollema Harry; Féty Regine; Van der Vijgh Wjf J F; Hempel Georg; Chatelut Etienne; Karlsson Mats; Wilkins Justin; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Christian; Beijnen Jos H; Schellens Jan H M
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Joerger M; Huitema A D R; Huizing M T; Willemse P H B; de Graeff A; Rosing H; Schellens J H M; Beijnen J H; Vermorken J B
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: Specenier P M; Van den Weyngaert D; Van Laer C; Weyler J; Van den Brande J; Huizing M T; Dyck J; Schrijvers D; Vermorken J B
Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(11):1856-60.
2007: Vermorken Jan B; Remenar Eva; van Herpen Carla; Gorlia Thierry; Mesia Ricard; Degardin Marian; Stewart John S; Jelic Svetislav; Betka Jan; Preiss Joachim H; van den Weyngaert Danielle; Awada Ahmad; Cupissol Didier; Kienzer Heinz R; Rey Augustin; Desaunois Isabelle; Bernier Jacques; Lefebvre Jean-Louis;
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
The New England journal of medicine 2007;357(17):1695-704.
2007: Specenier Pol M; Vermorken Jan B
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Cancer letters 2007;256(2):166-77.
2007: Asjoe Fernando Tjin; Altintas Sevilay; Colpaert Cecile; Marck Erik Van; Vermorken Jan B; Tjalma Wiebren A
The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.
The breast journal 2007;13(4):359-67.
2007: Van den Wyngaert Tim; Huizing Manon T; Vermorken Jan B
Osteonecrosis of the jaw related to the use of bisphosphonates.
Current opinion in oncology 2007;19(4):315-22.
2007: Wouters An; Pauwels Bea; Lardon Filip; Vermorken Jan B
Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions.
The oncologist 2007;12(6):690-712.
2007: Vermorken Jan B; Trigo José; Hitt Ricardo; Koralewski Piotr; Diaz-Rubio Eduardo; Rolland Frédéric; Knecht Rainald; Amellal Nadia; Schueler Armin; Baselga José
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2171-7.
2007: Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken J B
A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
British journal of cancer 2007;96(11):1692-8.
2007: Rasschaert Marika; Schrijvers Dirk; Van den Brande Jan; Dyck Joke; Bosmans Johan; Merkle Karlheinz; Vermorken Jan B
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Anti-cancer drugs 2007;18(5):587-95.
2007: Specenier Pol; Vermorken Jan B
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Current opinion in oncology 2007;19(3):195-201.
2007: Peters G J; Clavel M; Noordhuis P; Geyssen G J; Laan A C; Guastalla J; Edzes H T; Vermorken J B
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Journal of chemotherapy (Florence, Italy) 2007;19(2):212-21.
2007: Altintas S; Blockx N; Huizing M T; Van den Brande J; Hoekx L; Bogers J P; Van Marck E; Vermorken J B
Small-cell carcinoma of the penile urethra: a case report and a short review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):801-4.
2007: Baak Jan P A; van Diest Paul J; Voorhorst Feja J; van der Wall Elsken; Beex Louk V A M; Vermorken Jan B; Janssen Emiel A M; Gudlaugsson Einar;
The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.
European journal of cancer (Oxford, England : 1990) 2007;43(3):527-35.
2007: van Luijk I F; Coens C; van der Burg M E L; Kobierska A; Namer M; Lhomme C; Zola P; Zanetta G; Vermorken J B;
Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):275-81.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Féty Régine; de Bruijn Ernst; Hempel Georg; Karlsson Mats; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Chris; Beijnen Jos H; Schellens Jan H M;
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2006: Verhoeven Veronique; Baay Marc; Colliers Annelies; Verster Ann; Van Royen Paul; Avonts Dirk; Vermorken Jan B
The male factor in cervical carcinogenesis: a questionnaire study of men's awareness in primary care.
Preventive medicine 2006;43(5):389-93.
2006: Vermorken J B
Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x241-6.
2006: Van den Wyngaert T; Huizing M T; Vermorken J B
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1197-204.
2006: Pauwels Bea; Korst Annelies E C; Lambrechts Hilde A J; Pattyn Greet G O; de Pooter Christel M J; Lardon Filip; Vermorken Jan B
The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro.
Cancer chemotherapy and pharmacology 2006;58(2):219-28.
2006: Simoens Cindy; Vermorken Jan B; Korst Annelies E C; Pauwels Bea; De Pooter Christel M J; Pattyn Greet G O; Lambrechts Hilde A J; Breillout Fabienne; Lardon Filip
Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro.
Cancer chemotherapy and pharmacology 2006;58(2):210-8.
2006: Bernier Jacques; Vermorken Jan B; Koch Wayne M
Adjuvant therapy in patients with resected poor-risk head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(17):2629-35.
2006: Janssen Emiel A M; van Diest Paul J; Søiland Håvard; Gudlaugson Einar; Nysted Arne; Voorhorst Feja J; Vermorken Jan B; Søreide Jon-Arne; Baak Jan P A
Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2006;28(5-6):295-303.
2006: Pauwels Bea; Korst Annelies E C; Pattyn Greet G O; Lambrechts Hilde A J; Kamphuis Juliette A E; De Pooter Christel M J; Peters Godefridus J; Lardon Filip; Vermorken Jan B
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
BMC cancer 2006;6():142.
2006: Deschoolmeester Vanessa; Baay Marc; Wuyts Wim; Van Marck Eric; Pelckmans Paul; Lardon Filip; Vermorken Jan B
Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer.
Journal of clinical laboratory analysis 2006;20(2):52-61.
2005: Schrijvers Dirk; Vermorken Jan B
Taxanes in head and neck cancer.
Future oncology (London, England) 2005;1(6):829-39.
2005: Baay Marc F D; Tjalma Wiebren A A; Lambrechts Hilde A J; Pattyn Greet G O; Lardon Filip; Weyler Joost; Van Royen Paul; Van Marck Eric A E; Vermorken Jan B
Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35?
European journal of cancer (Oxford, England : 1990) 2005;41(17):2704-8.
2005: Pauwels Bea; Korst Annelies E C; Andriessen Veronique; Baay Marc F D; Pattyn Greet G O; Lambrechts Hilde A J; Pooter Christel M J De; Lardon Filip; Vermorken Jan B
Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53.
Radiation research 2005;164(5):642-50.
2005: Baak Jan P A; van Diest Paul J; Voorhorst Feja J; van der Wall Elsken; Beex Louk V A M; Vermorken Jan B; Janssen Emiel A M
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5993-6001.
2005: Van Putte Bart P; Hendriks Jeroen M H; Romijn Sander; Pauwels Bea; Vermorken Jan B; Van Schil Paul E Y
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
The Journal of thoracic and cardiovascular surgery 2005;130(1):125-30.
2005: Schrijvers Dirk; Vermorken Jan B
Taxanes in the treatment of head and neck cancer.
Current opinion in oncology 2005;17(3):218-24.
2005: Pauwels Bea; Korst Annelies E C; Lardon Filip; Vermorken Jan B
Combined modality therapy of gemcitabine and radiation.
The oncologist 2005;10(1):34-51.
2005: Quinn M; Avall-Lundqvist E; du Bois A; Vermorken J; Parmar M; Pfisterer J; Stuart G; Thigpen T; Neijt J
History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii5-viii6.
2005: Vermorken J B; Avall-Lundqvist E; Pfisterer J; Bacon M;
The Gynecologic Cancer Intergroup (GCIG): history and current status.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii39-viii42.
2005: Vermorken J B
Medical treatment in head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii258-64.
2004: Duffaud F; Borner M; Chollet P; Vermorken J B; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
European journal of cancer (Oxford, England : 1990) 2004;40(18):2748-52.
2004: Hendriks Jeroen M H; Grootenboers Marco J J H; Schramel Franz M N H; van Boven Wim J; Stockman Bernard; Seldenrijk Cornelis A; ten Broecke Pieter; Knibbe Catherijne A J; Slee Peter; De Bruijn Ernst; Vlaeminck Renate; Heeren Jos; Vermorken Jan B; van Putte Bart; Romijn Sander; Van Marck Eric; Van Schil Paul E Y
Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial.
The Annals of thoracic surgery 2004;78(6):1919-26; discussion 1926-7.
2004: Verhoeven V; Baay M; Weyler J; Avonts D; Lardon F; Van Royen P; Vermorken J B
Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2004;23(9):735-7.
2004: Baay Marc F D; Kjetland Eyrun F; Ndhlovu Patricia D; Deschoolmeester Vanessa; Mduluza Takafira; Gomo Exenevia; Friis Henrik; Midzi Nicholas; Gwanzura Lovemore; Mason Peter R; Vermorken Jan B; Gundersen Svein G
Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution.
Journal of medical virology 2004;73(3):481-5.
2004: Schrijvers D; Van Herpen C; Kerger J; Joosens E; Van Laer C; Awada A; Van den Weyngaert D; Nguyen H; Le Bouder C; Castelijns J A; Kaanders J; De Mulder P; Vermorken J B
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(4):638-45.
2004: Pignata Sandro; Vermorken Jan B
Ovarian cancer in the elderly.
Critical reviews in oncology/hematology 2004;49(1):77-86.
2004: Baay Marc F D; Smits Evelien; Tjalma Wiebren A A; Lardon Filip; Weyler Joost; Van Royen Paul; Van Marck Eric A E; Vermorken Jan B
Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women.
International journal of cancer. Journal international du cancer 2004;108(2):258-61.
2004: Baay M F D; Verhoeven V; Avonts D; Vermorken J B
Risk factors for cervical cancer development: what do women think?
Sexual health 2004;1(3):145-9.
2004: Baay M F D; Weyler J; Vermorken J B
The value of human papillomavirus detection in primary cervical cancer screening.
European journal of gynaecological oncology 2004;25(6):665-9.
2004: Baay Marc; Verhoeven Veronique; Wouters Kristien; Lardon Filip; Van Damme Pierre; Avonts Dirk; Van Marck Eric; Van Royen Paul; Vermorken Jan B
The prevalence of the human papillomavirus in cervix and vagina in low-risk and high-risk populations.
Scandinavian journal of infectious diseases 2004;36(6-7):456-9.
2004: Mebis J; De Raeve H; Baekelandt M; Tjalma W A A; Vermorken J B
Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature.
European journal of gynaecological oncology 2004;25(2):239-41.
2003: Simoens C; Korst A E C; De Pooter C M J; Lambrechts H A J; Pattyn G G O; Faircloth G T; Lardon F; Vermorken J B
In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
British journal of cancer 2003;89(12):2305-11.
2003: Piccart M J; Floquet A; Scarfone G; Willemse P H B; Emerich J; Vergote I; Giurgea L; Coens C; Awada A; Vermorken J B
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():196-203.
2003: Vermorken J B
The role of anthracyclines in second-line therapy of ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():178-84.
2003: Pauwels Bea; Korst Annelies E C; Pattyn Greet G O; Lambrechts Hilde A J; Van Bockstaele Dirk R; Vermeulen Katrien; Lenjou Marc; de Pooter Christel M J; Vermorken Jan B; Lardon Filip
Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro.
International journal of radiation oncology, biology, physics 2003;57(4):1075-83.
2003: Twelves C; Hoekman K; Bowman A; Vermorken J B; Anthoney A; Smyth J; van Kesteren C; Beijnen J H; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1842-51.
2003: Aapro M S; van Wijk F H; van der Burg M E L; ten Bokkel Huinink W; Vergote I; Guastalla J P; Rosso R; Kobierska A; Beex L V A; Namer M; Splinter T E W; Vermorken J B
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1141-3.
2003: Pauwels B; Korst A E C; de Pooter C M J; Lambrechts H A J; Pattyn G G O; Lardon F; Vermorken J B
The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro.
European journal of cancer (Oxford, England : 1990) 2003;39(6):838-46.
2003: van Rijswijk R E N; Vermorken J B; Reed N; Favalli G; Mendiola C; Zanaboni F; Mangili G; Vergote I; Guastalla J P; ten Bokkel Huinink W W; Lacave A J; Bonnefoi H; Tumulo S; Rietbroek R; Teodorovic I; Coens C; Pecorelli S
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
European journal of cancer (Oxford, England : 1990) 2003;39(4):481-7.
2003: Van den Brande J; Schöffski P; Schellens J H M; Roth A D; Duffaud F; Weigang-Köhler K; Reinke F; Wanders J; de Boer R F; Vermorken J B; Fumoleau P
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
British journal of cancer 2003;88(5):648-53.
2003: Pauwels Bea; Korst Annelies E C; de Pooter Christel M J; Pattyn Greet G O; Lambrechts Hilde A J; Baay Marc F D; Lardon Filip; Vermorken Jan B
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies.
Cancer chemotherapy and pharmacology 2003;51(3):221-6.
2003: Vermorken Jan B; Van Tendeloo Viggo F I
Dendritic cell therapy of cancer: can it fulfill its promise?
Expert review of anticancer therapy 2003;3(1):1-3.
2003: Hendriks J M H; van Putte B; Romijn S; van den Brande J; Vermorken J B; van Schil P E
Pneumonectomy for lung metastases: report of ten cases.
The Thoracic and cardiovascular surgeon 2003;51(1):38-41.
2003: Trimbos J Baptist; Vergote Ignace; Bolis Giorgio; Vermorken Jan B; Mangioni Constantino; Madronal Caterina; Franchi Massimo; Tateo Saverio; Zanetta Gerardo; Scarfone Giovanna; Giurgea Livia; Timmers Petra; Coens Corneel; Pecorelli Sergio;
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Journal of the National Cancer Institute 2003;95(2):113-25.
2003: Trimbos J Baptist; Parmar Mahesh; Vergote Ignace; Guthrie David; Bolis Giorgio; Colombo Nicoletta; Vermorken Jan B; Torri Valter; Mangioni Constantino; Pecorelli Sergio; Lissoni Andrea; Swart Ann Marie;
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Journal of the National Cancer Institute 2003;95(2):105-12.
2003: van Wijk F H; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira C F; Vermorken J B;
Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
European journal of cancer (Oxford, England : 1990) 2003;39(1):78-85.
2002: Schrijvers Dirk; Vermorken Jan B
Phase I studies with bendamustine: an update.
Seminars in oncology 2002;29(4 Suppl 13):15-8.
2002: van Outryve S; Schrijvers D; van den Brande J; Wilmes P; Bogers J; van Marck E; Vermorken J B
Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.
The Netherlands journal of medicine 2002;60(5):216-22.
2002: van Kesteren Charlotte; Twelves Chris; Bowman Angela; Hoekman Klaas; López-Lázaro Luis; Jimeno José; Guzman Cecilia; Mathôt Ron A A; Simpson Andrew; Vermorken Jan B; Smyth John; Schellens Jan H M; Hillebrand Michel J X; Rosing Hilde; Beijnen Jos H
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Anti-cancer drugs 2002;13(4):381-93.
2002: Baars A; Claessen A M E; Wagstaff J; Giaccone G; Scheper R J; Meijer S; Schakel M J A G; Gall H E; Meijer C J L M; Vermorken J B; Pinedo H M; van den Eertwegh A J M
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
British journal of cancer 2002;86(8):1230-4.
2002: Schöffski P; Herr A; Vermorken J B; Van den Brande J; Beijnen J H; Rosing H; Volk J; Ganser A; Adank S; Botma H J; Wanders J
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
European journal of cancer (Oxford, England : 1990) 2002;38(6):807-13.
2002: Schrijvers D; Bos A M E; Dyck J; de Vries E G E; Wanders J; Roelvink M; Fumoleau P; Bortini S; Vermorken J B
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):385-91.
2002: Michalides R; van Tinteren H; Balkenende A; Vermorken J B; Benraadt J; Huldij J; van Diest P
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.
British journal of cancer 2002;86(3):402-8.
2001: Hendriks J M; Romijn S; Van Putte B; Eyskens E; Vermorken J B; Van Marck E; Van Schil P E
Long-term results of surgical resection of lung metastases.
Acta chirurgica Belgica 2001;101(6):267-72.
2001: Bos A M; de Vries E G; Dombernovsky P; Aamdal S; Uges D R; Schrijvers D; Wanders J; Roelvink M W; Hanauske A R; Bortini S; Capriati A; Crea A E; Vermorken J B
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Cancer chemotherapy and pharmacology 2001;48(5):361-9.
2001: Wagenaar H C; Pecorelli S; Mangioni C; van der Burg M E; Rotmensz N; Anastasopoulou A; Zola P; Veenhof C H; Lacave A J; Neijt J P; van Oosterom A T; Einhorn N; Vermorken J B
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1624-8.
2001: Van den Brande J; Nannan Panday V R; Hoekman K; Rosing H; Huijskes R V; Verheijen R H; Beijnen J H; Vermorken J B
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
American journal of clinical oncology 2001;24(4):401-3.
2001: Tjalma W A; Weyler J J; Bogers J J; Pollefliet C; Baay M; Goovaerts G C; Vermorken J B; van Dam P A; van Marck E A; Buytaert P M
The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer.
European journal of obstetrics, gynecology, and reproductive biology 2001;97(2):223-30.
2001: Vermorken J B; Zanetta G; De Oliveira C F; van der Burg M E; Lacave A J; Teodorovic I; Boes G H; Colombo N
Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(7):967-74.
2001: Wagenaar H C; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave A J; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla J P; Nooij M A; Poveda A; Scotto di Palumbo V; Vermorken J B
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Gynecologic oncology 2001;81(3):348-54.
2001: Duffaud F; van der Burg M E; Namer M; Vergote I; Willemse PHB; ten Bokkel Huinink W; Guastalla J P; Nooij; Kerbrat P; Piccart M; Tumolo S; Favalli G; van der Vange N; Lacave A J; Wils J; Splinter T A; Einhorn N; Roozendaal K J; Rosso R; Vermorken J B
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
Anti-cancer drugs 2001;12(2):159-62.
2001: Baay M F; Tjalma W A; Weyler J; Pattyn G G; Lambrechts H A; Goovaerts G; Baekelandt M; Buytaert P; Van Marck E A; Lardon F; Vermorken J B
Prevalence of human papillomavirus in elderly women with cervical cancer.
Gynecologic and obstetric investigation 2001;52(4):248-51.
2001: Baay M F; Tjalma W A; Weyler J; Goovaerts G; Buytaert P; Van Marck E A; Lardon F; Vermorken J B
Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer.
European journal of gynaecological oncology 2001;22(3):204-8.
2001: Wagenaar H C; Pecorelli S; Vergote I; Curran D; Wagener D J; Kobierska A; Bolis G; Bokkel-Huinink W T; Lacave A J; Madronal C; Forn M; de Oliveira C F; Mangioni C; Nooij M A; Goupil A; Kerbrat P; Marth C H; Tumolo S; Herben M G; Zanaboni F; Vermorken J B
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
European journal of gynaecological oncology 2001;22(3):187-93.
2001: Vermorken J B
Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11 Suppl 1():73-6.
2001: Vermorken J B
The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11 Suppl 1():21-30.
2000: Vermorken J B
Adjuvant immunotherapy in colorectal cancer.
Seminars in oncology 2000;27(5 Suppl 10):66-71.
2000: Vermorken J B; Kobierska A; Chevallier B; Zanaboni F; Pawinski A; Bolis G
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):1035-40.
2000: Baars A; Claessen A M; van den Eertwegh A J; Gall H E; Stam A G; Meijer S; Giaccone G; Meijer C J; Scheper R J; Wagstaff J; Vermorken J B; Pinedo H M
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):965-70.
2000: van Rijswijk R E; Vermorken J B
Drug therapy for gynaecological cancer in older women.
Drugs & aging 2000;17(1):13-32.
2000: Postma T J; Heimans J J; Luykx S A; van Groeningen C J; Beenen L F; Hoekstra O S; Taphoorn M J; Zonnenberg B A; Klein M; Vermorken J B
A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):409-13.
2000: Mentens Y; Schrijvers D; Van den Brande J; Van Schil P; Vermorken J B
Thoracic wall prosthesis prevents deep invasion by non-small-cell lung cancer.
American journal of clinical oncology 2000;23(1):32-3.
2000: Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken J B
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
British journal of cancer 2000;82(2):291-4.
2000: Vermorken J B
Optimal treatment for ovarian cancer: taxoids and beyond.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():131-9.
2000: Damen J; Schrijvers D; Van Den Brande J; Pelgrims J; Vermorken J
Intraperitoneal treatment of peritoneo-venous shunt infection in a cancer patient.
Scandinavian journal of infectious diseases 2000;32(1):106.
1999: Kroep J R; Peters G J; van Moorsel C J; Catik A; Vermorken J B; Pinedo H M; van Groeningen C J
Gemcitabine-cisplatin: a schedule finding study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(12):1503-10.
1999: Van den Brande J; Schrijvers D; Colpaert C; Vermorken J B
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1369-72.
1999: Pecorelli S; Wagenaar H C; Vergote I B; Curran D; Beex L V; Wiltshaw E; Vermorken J B
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study.
European journal of cancer (Oxford, England : 1990) 1999;35(9):1331-7.
1999: Welink J; Boven E; Vermorken J B; Gall H E; van der Vijgh W J
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2349-58.
1999: Vermorken J B; ten Bokkel Huinink W W; Kobierska A; van der Burg M E; Forni M; Piccart M J; van der Putten E
Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma.
Oncology 1999;57(1):10-6.
1999: Panday V R; ten Bokkel Huinink W W; Vermorken J B; Rosing H; Koopman F J; Swart M; Schellens J H; Beijnen J H
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: van Moorsel C J; Pinedo H M; Veerman G; Bergman A M; Kuiper C M; Vermorken J B; van der Vijgh W J; Peters G J
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
British journal of cancer 1999;80(7):981-90.
1999: van Moorsel C J; Pinedo H M; Veerman G; Vermorken J B; Postmus P E; Peters G J
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
European journal of cancer (Oxford, England : 1990) 1999;35(5):808-14.
1999: van Moorsel C J; Kroep J R; Pinedo H M; Veerman G; Voorn D A; Postmus P E; Vermorken J B; van Groeningen C J; van der Vijgh W J; Peters G J
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):441-8.
1999: Schrijvers D; Highley M; De Bruyn E; Van Oosterom A T; Vermorken J B
Role of red blood cells in pharmacokinetics of chemotherapeutic agents.
Anti-cancer drugs 1999;10(2):147-53.
1999: van Moorsel C J; Pinedo H M; Veerman G; Guechev A; Smid K; Loves W J; Vermorken J B; Postmus P E; Peters G J
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Biochemical pharmacology 1999;57(4):407-15.
1999: van Gijn R; ten Bokkel Huinink W W; Rodenhuis S; Vermorken J B; van Tellingen O; Rosing H; van Warmerdam L J; Beijnen J H
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1999: Vermorken J B; Claessen A M; van Tinteren H; Gall H E; Ezinga R; Meijer S; Scheper R J; Meijer C J; Bloemena E; Ransom J H; Hanna M G; Pinedo H M
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
Lancet 1999;353(9150):345-50.
1999: Postma T J; Hoekman K; van Riel J M; Heimans J J; Vermorken J B
Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
Journal of neuro-oncology 1999;45(3):241-6.
1999: Vermorken J B; Harper P G; Buyse M
The role of anthracyclines in epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():43-50.
1998: Schrijvers D; Van den Brande J; Vermorken J B
Pulmonary embolism.
The New England journal of medicine 1998;339(21):1555; author reply 1557.
1998: Rosing H; Hillebrand M J; Jimeno J M; Gómez A; Floriano P; Faircloth G; Henrar R E; Vermorken J B; Cvitkovic E; Bult A; Beijnen J H
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 1998;33(11):1134-40.
1998: Schrijvers D; Tai-Apin C; De Smet M C; Cornil P; Vermorken J B; Bruyneel P
Determination of compatibility and stability of drugs used in palliative care.
Journal of clinical pharmacy and therapeutics 1998;23(4):311-4.
1998: Postma T J; Heimans J J; Muller M J; Ossenkoppele G J; Vermorken J B; Aaronson N K
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):739-44.
1998: Rosing H; Hillebrand M J; Jimeno J M; Gómez A; Floriano P; Faircloth G; Cameron L; Henrar R E; Vermorken J B; Bult A; Beijnen J H
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1998;710(1-2):183-9.
1998: Schrijvers D; Vermorken J B
Update on the taxoids and other new agents in head and neck cancer therapy.
Current opinion in oncology 1998;10(3):233-41.
1998: Korst A E; van der Sterre M L; Gall H E; Fichtinger-Schepman A M; Vermorken J B; van der Vijgh W J
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):331-6.
1998: Nannan Panday V R; van Warmerdam L J; Huizing M T; Ten Bokkel Huinink W W; Vermorken J B; Giaccone G; Veenhof C H; Schellens J H; Beijnen J H
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: van Moorsel C J; Veerman G; Vermorken J B; Voorn D A; Kroep J R; Bergman A M; Pinedo H M; Peters G J
Mechanisms of synergism between gemcitabine and cisplatin.
Advances in experimental medicine and biology 1998;431():581-5.
1997: van Rijswijk R E; Hoekman K; Burger C W; Verheijen R H; Vermorken J B
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1235-41.
1997: Giaccone G; Linn S C; Welink J; Catimel G; Stieltjes H; van der Vijgh W J; Eeltink C; Vermorken J B; Pinedo H M
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2005-15.
1997: Mulder W M; Stern P L; Stukart M J; de Windt E; Butzelaar R M; Meijer S; Adér H J; Claessen A M; Vermorken J B; Meijer C J; Wagstaff J; Scheper R J; Bloemena E
Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):1923-30.
1997: Honkoop A H; van der Wall E; Feller N; Schuurhuis G J; van der Vijgh W J; Boven E; van Groeningen C J; Giaccone G; Hoekman K; Vermorken J B; Wagstaff J; Pinedo H M
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):957-62.
1997: Korst A E; Eeltink C M; Vermorken J B; van der Vijgh W J
Pharmacokinetics of amifostine and its metabolites in patients.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1425-9.
1997: Panday V R; Huizing M T; Willemse P H; De Graeff A; ten Bokkel Huinink W W; Vermorken J B; Beijnen J H
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Seminars in oncology 1997;24(4 Suppl 11):S11-34-S11-38.
1997: Korst A E; van der Sterre M L; Eeltink C M; Fichtinger-Schepman A M; Vermorken J B; van der Vijgh W J
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):697-703.
1997: Korst A E; Vermorken J B; van der Vijgh W J
High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(1):167-74.
1997: Linn S C; Pinedo H M; van Ark-Otte J; van der Valk P; Hoekman K; Honkoop A H; Vermorken J B; Giaccone G
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.
International journal of cancer. Journal international du cancer 1997;71(5):787-95.
1997: van Moorsel C J; Veerman G; Bergman A M; Guechev A; Vermorken J B; Postmus P E; Peters G J
Combination chemotherapy studies with gemcitabine.
Seminars in oncology 1997;24(2 Suppl 7):S7-17-S7-23.
1997: Huizing M T; Giaccone G; van Warmerdam L J; Rosing H; Bakker P J; Vermorken J B; Postmus P E; van Zandwijk N; Koolen M G; ten Bokkel Huinink W W; van der Vijgh W J; Bierhorst F J; Lai A; Dalesio O; Pinedo H M; Veenhof C H; Beijnen J H
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):317-29.
1997: Vermorken J B; Guastalla J P; Hatty S R; Seitz D E; Tanis B; McDaniels C; Clavel M D
Phase I study of gemcitabine using a once every 2 weeks schedule.
British journal of cancer 1997;76(11):1489-93.
1996: Verweij J; de Mulder P H; de Graeff A; Vermorken J B; Wildiers J; Kerger J; Schornagel J; Cognetti F; Kirkpatrick A; Sahmoud T; Lefebvre J L
Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):867-9.
1996: Honkoop A H; Hoekman K; Wagstaff J; van Groeningen C J; Vermorken J B; Boven E; Pinedo H M
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
British journal of cancer 1996;74(7):1132-6.
1996: von Mensdorff-Pouilly S; Gourevitch M M; Kenemans P; Verstraeten A A; Litvinov S V; van Kamp G J; Meijer S; Vermorken J; Hilgers J
Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1325-31.
1996: van Haperen V W; Veerman G; Vermorken J B; Pinedo H M; Peters G
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
Biochemical pharmacology 1996;51(7):911-8.
1996: Hoekman K; Tognon G; Risse E K; Bloemsma C A; Vermorken J B
Well-differentiated papillary mesothelioma of the peritoneum: a separate entity.
European journal of cancer (Oxford, England : 1990) 1996;32A(2):255-8.
1996: Honkoop A H; Hoekman K; Wagstaff J; Boven E; van Groeningen C J; Giaccone G; Vermorken J B; Pinedo H M
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):35-9.
1996: Korst A E; Gall H E; Vermorken J B; van der Vijgh W J
Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Cancer chemotherapy and pharmacology 1996;39(1-2):162-6.
1996: Veerman G; Ruiz van Haperen V W; Vermorken J B; Noordhuis P; Braakhuis B J; Pinedo H M; Peters G J
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Cancer chemotherapy and pharmacology 1996;38(4):335-42.
1995: van Gijn R; Havik E; Boven E; Vermorken J B; ten Bokkel Huinink W W; van Tellingen O; Beijnen J H
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: Huizing M T; Vermorken J B; Rosing H; ten Bokkel Huinink W W; Mandjes I; Pinedo H M; Beijnen J H
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):699-704.
1995: Vermorken J B; Hoekman K
Chemotherapy for gynecologic malignancies.
Current opinion in oncology 1995;7(5):457-65.
1995: Giaccone G; Huizing M; Postmus P E; ten Bokkel Huinink W W; Koolen M; van Zandwijk N; Vermorken J B; Beijnen J H; Dalesio O; Pinedo H M
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):78-82.
1995: Vermorken J B; ten Bokkel Huinink W W; Mandjes I A; Postma T J; Huizing M T; Heimans J J; Beijnen J H; Bierhorst F; Winograd B; Pinedo H M
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Seminars in oncology 1995;22(4 Suppl 8):16-22.
1995: Schornagel J H; Verweij J; de Mulder P H; Cognetti F; Vermorken J B; Cappelaere P; Armand J P; Wildiers J; de Graeff A; Clavel M
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1649-55.
1995: Postma T J; Vermorken J B; Liefting A J; Pinedo H M; Heimans J J
Paclitaxel-induced neuropathy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):489-94.
1995: van Gijn R; van Tellingen O; de Clippeleir J J; Hillebrand M J; Boven E; Vermorken J B; ten Bokkel Huinink W W; Schwertz S; Graf P; Beijnen J H
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: Hoekman K; Huijskes R V; Burger C W; Verheijen R H; Pinedo H M; Vermorken J B
[Favorable results of paclitaxel (Taxol) in patients with ovary carcinoma pretreated with platinum]
Nederlands tijdschrift voor geneeskunde 1995;139(6):272-8.
1995: Vermorken J B; Kobierska A; van der Burg M E; Chevallier B; Zanaboni F; ten Bokkel Huinink W W; Forni M; Pawinski A; van der Putten E; Bolis G
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.
European journal of gynaecological oncology 1995;16(6):433-8.
1995: Boer H H; Moorer-van Delft C M; Müller L J; Kiburg B; Vermorken J B; Heimans J J
Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis.
Journal of neuro-oncology 1995;25(1):49-57.
1995: Huizing M T; Misser V H; Pieters R C; ten Bokkel Huinink W W; Veenhof C H; Vermorken J B; Pinedo H M; Beijnen J H
Taxanes: a new class of antitumor agents.
Cancer investigation 1995;13(4):381-404.
1995: van der Vange N; Greggi S; Burger C W; Kenemans P; Vermorken J B
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Acta oncologica (Stockholm, Sweden) 1995;34(6):813-20.
1994: Heimans J J; Vermorken J B; Wolbers J G; Eeltink C M; Meijer O W; Taphoorn M J; Beijnen J H
Paclitaxel (Taxol) concentrations in brain tumor tissue.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(10):951-3.
1994: Ruiz van Haperen V W; Veerman G; Boven E; Noordhuis P; Vermorken J B; Peters G J
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Biochemical pharmacology 1994;48(7):1327-39.
1994: Beijnen J H; Huizing M T; ten Bokkel Huinink W W; Veenhof C H; Vermorken J B; Giaccone G; Pinedo H M
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Seminars in oncology 1994;21(5 Suppl 8):53-62.
1994: Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Seminars in oncology 1994;21(5 Suppl 8):34-8.
1994: Ruiz van Haperen V W; Veerman G; Eriksson S; Boven E; Stegmann A P; Hermsen M; Vermorken J B; Pinedo H M; Peters G J
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Cancer research 1994;54(15):4138-43.
1994: Clavel M; Vermorken J B; Cognetti F; Cappelaere P; de Mulder P H; Schornagel J H; Tueni E A; Verweij J; Wildiers J; Clerico M
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):521-6.
1994: Hoekman K; Wagstaff J; Vermorken J B; Meijer S; Meijer O W; Pinedo H M
[Primary high-dose chemotherapy with hematopoietic growth factors followed by surgery and radiotherapy in stage III breast carcinoma; a Phase II study in 15 patients]
Nederlands tijdschrift voor geneeskunde 1994;138(21):1069-73.
1994: Hoekman K; van Doorn J; Gloudemans T; Hoekstra O S; Maassen J A; Vermorken J B; Wagstaff J; Pinedo H M
Tumour-induced hypoglycaemia: a case report.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):277-81.
1994: Vermorken J B; Bolis G; van Rijswijk R E; Kobierska A; Chevallier B; van der Burg M E; Zanaboni F; Lentz M A; Burger C W; Kenemans P
High-dose intensity regimens with epirubicin in ovarian cancer.
Seminars in oncology 1994;21(1 Suppl 1):17-22.
1994: De Mulder P H; Cappelaere P; Cognetti F; Verweij J; Schornagel J H; Vermorken J B; Kirkpatrick A; Lefebvre J L
A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.
Cancer chemotherapy and pharmacology 1994;33(5):438-40.
1994: Vermorken J B
Consolidation therapy in patients with advanced ovarian cancer.
European journal of gynaecological oncology 1994;15(1):7-13.
1994: Guastalla J P; Vermorken J B; Wils J A; George M; Scotto V; Nooij M; ten Bokkel Huinnink W W; Dalesio O; Renard J
Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.
European journal of cancer (Oxford, England : 1990) 1994;30A(1):45-9.
1994: Veenhof C H; van der Burg M E; Nooy M; Aalders J G; Pecorelli S; Oliveira C F; Rotmensz N; Vermorken J B
Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(5):697-8.
1994: Tumolo S; Rao B R; van der Burg M E; Guastalla J P; Renard J; Vermorken J B
Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):911-4.
1993: Vermorken J B; Verweij J; de Mulder P H; Cognetti F; Clavel M; Rodenhuis S; Kirkpatrick A; Snow G B
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):785-8.
1993: Ruiz van Haperen V W; Veerman G; Vermorken J B; Peters G J
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
Biochemical pharmacology 1993;46(4):762-6.
1993: Pieters R C; Vermorken J B; Gall H E; Nauta J J; van Loenen A C; van Groeningen C J; van Rijswijk R E; Brenninkmeijer J H; Pinedo H M
A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy.
Oncology 1993;50(4):316-22.
1993: Yedema C A; Kenemans P; Voorhorst F; Bon G; Schijf C; Beex L; Verstraeten A; Hilgers J; Vermorken J
CA 125 half-life in ovarian cancer: a multivariate survival analysis.
British journal of cancer 1993;67(6):1361-7.
1993: van Gijn R; Rosing H; ten Bokkel Huinink W W; van Tellingen O; Vermorken J B; Liefting A J; Bruno R; Pinedo H M; Beijnen J H
Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;614(2):299-306.
1993: Vermorken J B; Gundersen S; Clavel M; Smyth J F; Dodion P; Renard J; Kaye S B
Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(4):303-6.
1993: Richters C D; Burger C W; van de Loosdrecht A A; van Rijswijk R E; Calame W; Bleker O P; Vermorken J B; Kenemans P; Beelen R H
The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment.
Cancer letters 1993;68(1):25-31.
1993: Vermorken J B; ten Bokkel Huinink W W; Eisenhauer E A; Favalli G; Belpomme D; Conte P F; Kaye S B
Advanced ovarian cancer. Carboplatin versus cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():41-8.
1993: Ruiz van Haperen V W; Veerman G; Braakhuis B J; Vermorken J B; Boven E; Leyva A; Peters G J
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2132-7.
1992: de Jong J; Geijssen G J; Munniksma C N; Vermorken J B; van der Vijgh W J
Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1897-906.
1992: Vermorken J B
High-dose intensity regimens with epirubicin in ovarian cancer.
Pathologie-biologie 1992;39(9):833.
1992: de Jong J; Vermorken J B; van der Vijgh W J
Analysis and pharmacokinetics of a new prodrug N-l-leucyldoxorubicin and its metabolites in plasma using HPLC with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1992;10(4):309-14.
1992: Schornagel J H; Verweij J; de Mulder P H; Cognetti F; Vermorken J B; Cappelaere P; Armand J P; Wildiers J; Clavel M; Kirkpatrick A
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):223-6.
1992: Müller L J; Moorer-van Delft C M; Roubos E W; Vermorken J B; Boer H H
Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Cancer research 1992;52(4):963-73.
1992: Tanis B C; Vermorken J B; ten Bokkel Huinink W W; van Oosterom A T; Splinter T A; Vendrik K J; Sleijfer D T; van der Burg M E; van der Putten E; Pinedo H M
Multicenter phase II study of spiroplatin.
Oncology 1992;49(2):99-103.
1992: Nijman H W; Burger C W; Baak J P; Schats R; Vermorken J B; Kenemans P
Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases.
European journal of cancer (Oxford, England : 1990) 1992;28A(12):1971-3.
1992: van der Burg M E; Monfardini S; Guastalla J P; de Oliveira C; Renard J; Vermorken J B
Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):147-8.
1991: Yedema K A; Kenemans P; Wobbes T; van Kamp G J; de Bruijn H W; Thomas C M; Massuger L F; Schijf C P; Bon G G; Vermorken J B
Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
International journal of cancer. Journal international du cancer 1991;47(2):170-9.
1991: Oosterkamp H M; Vlasveld L T; Wanders J; Beijnen J H; van Tellingen O; Dubbelman A C; Simonetti G P; Franklin H R; Vermorken J B; Ten Bokkel Huinink W W
Phase I study of vintriptol, a tryptophan ester of vinblastine.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1222-6.
1991: Tanis B C; Vermorken J B; ten Bokkel Huinink W W; Klein I; Gall H; van Oosterom A T; Simonetti G; McVie J G; van der Vijgh W J; Pinedo H M
Phase I study of spiroplatin.
European journal of cancer (Oxford, England : 1990) 1991;27(3):268-73.
1991: Ruiz van Haperen V W; Veerman G; Noordhuis P; Vermorken J B; Peters G J
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Advances in experimental medicine and biology 1991;309A():57-60.
1991: Vermorken J B; Tumolo S; Roozendaal K J; Guastalla J P; Splinter T A; Renard J
5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix.
European journal of cancer (Oxford, England : 1990) 1991;27(2):216-7.
1990: De Mulder P H; Seynaeve C; Vermorken J B; van Liessum P A; Mols-Jevdevic S; Allman E L; Beranek P; Verweij J
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Annals of internal medicine 1990;113(11):834-40.
1990: Verweij J; Schornagel J; de Mulder P; Henzen-Logmans S; Cognetti F; Clavel M; Vermorken J
Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.
Cancer 1990;66(9):1910-3.
1990: Schuurhuis G J; Broxterman H J; Pinedo H M; van Heijningen T H; van Kalken C K; Vermorken J B; Spoelstra E C; Lankelma J
The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
British journal of cancer 1990;62(4):591-4.
1990: Vermorken J B
Chemotherapy and new treatments in squamous cell carcinoma of the head and neck.
Current opinion in oncology 1990;2(3):578-84.
1990: Durrant K R; Mangioni C; Lacave A J; George M; van der Burg M E; Guthrie D; Rotmenz N; Dalesio O; Vermorken J B
Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG).
Gynecologic oncology 1990;37(3):359-62.
1990: Schwartsmann G; Dodion P; Vermorken J B; ten Bokkel Huinink W W; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh W J; van Hennik M B
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Cancer chemotherapy and pharmacology 1990;25(5):345-51.
1989: van Groeningen C J; Gall H E; Simons K A; van Loenen A C; Knobf M K; Nauta J; Vermorken J B; Pinedo H M
Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.
The Netherlands journal of medicine 1989;35(5-6):283-94.
1989: Schwartsmann G; van der Vijgh W J; van Hennik M B; Klein I; Vermorken J B; Dodion P; ten Bokkel Huinink W W; Joggi G; Gall H; Crespeigne N
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
European journal of cancer & clinical oncology 1989;25(12):1675-81.
1989: Wagstaff J; Vermorken J B; Schwartsmann G; Scheper R J; Hack C E; Nuijens J H; Eerenberg-Belmer A J; Pinedo H M
A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2.
Cancer treatment reviews 1989;16 Suppl A():105-9.
1989: Schwartsmann G; Bork E; Vermorken J B; Nieboer C; Dodion P; ten Bokkel Huinink W W; Seldenrijk C A; Armand J P; Pinedo H M
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Cancer 1989;63(2):243-8.
1989: Neijt J P; van der Burg M E; Guastalla J P; George M; Piccart M; Vermorken J; Carnino F; Rotmensz N
Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.
Acta oncologica (Stockholm, Sweden) 1989;28(5):663-5.
1988: van Oosterom A T; Aapro M S; Carnino F; van der Burg M E; Pecorelli S; Rotmensz N; Dalesio O; Vermorken J B
Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group.
European journal of cancer & clinical oncology 1988;24(8):1379-80.
1988: ten Bokkel Huinink W W; van der Burg M E; van Oosterom A T; Neijt J P; George M; Guastalla J P; Veenhof C H; Rotmensz N; Dalesio O; Vermorken J B
Carboplatin in combination therapy for ovarian cancer.
Cancer treatment reviews 1988;15 Suppl B():9-15.
1988: van der Vijgh W J; Elferink F; Vermorken J B; ten Bokkel Huinink W W; Klein I; Gall H E; Simonetti G; McVie J G; Pinedo H M
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
European journal of cancer & clinical oncology 1988;24(4):621-7.
1988: Lankelma J; Stuurman M; van Hoogenhuijze J; van Bochove A; Vermorken J B; Verweij J; Pinedo H M
The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration.
European journal of cancer & clinical oncology 1988;24(2):175-80.
1987: Elferink F; van der Vijgh W J; Klein I; Vermorken J B; Gall H E; Pinedo H M
Pharmacokinetics of carboplatin after i.v. administration.
Cancer treatment reports 1987;71(12):1231-7.
1987: van Hennik M B; van der Vijgh W J; Klein I; Elferink F; Vermorken J B; Winograd B; Pinedo H M
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
Cancer research 1987;47(23):6297-301.
1987: Elferink F; van der Vijgh W J; ten Bokkel Huinink W W; Vermorken J B; Klein I; Winograd B; Knobf M K; Simonetti G; Gall H E; McVie J G
Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
British journal of cancer 1987;56(4):479-83.
1987: van der Burg M E; ten Bokkel Huinink W W; Vriesendorp R; van Oosterom A T; Neijt J P; Vermorken J B; van Putten W L; Kooiman A
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
European journal of cancer & clinical oncology 1987;23(7):997-8.
1987: George M; Scotto V; Carnino F; Dodion P; ten Bokkel Huinink W W; Rotmensz N; Vermorken J B
Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.
European journal of cancer & clinical oncology 1987;23(6):867-9.
1986: Cognetti F; Clerico M; Vermorken J; Van Rymenant M; Rossi A; Kirkpatrick A; Dalesic O; Clavel M
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
European journal of cancer & clinical oncology 1986;22(7):891-2.
1986: Winograd B; Vermorken J B; ten Bokkel Huinink W W; Simonetti G; Gall H E; Knobf M K; van der Vijgh W J; McVie J G; Pinedo H M
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Cancer research 1986;46(4 Pt 2):2148-51.
1985: Hamerlynck J V; Maskens A P; Mangioni C; van der Burg M E; Wils J A; Vermorken J B; Rotmensz N
Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
Gynecologic oncology 1985;22(3):313-6.
1985: Vermorken J B; Armand J P; Lacave A J; George M; de Oliveira C F; Cheix F; Maskens A P; Rotmensz N
Phase II trial of bleomycin in patients with advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
European journal of cancer & clinical oncology 1985;21(6):671-3.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jan Vermorken

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jan Vermorken (preview)

All Publications